The basis for the company's strategic direction will be highlighted. Furthermore, the major medical needs in primary mitochondrial disease, the competitive situation and the market. The opportunities in the field of orphan drugs will be addressed.
The plans and clinical developments for the key projects KL1333 and NV354 will also be described.
External as well as internal participators will provide a clinical perspective and an investor perspective on Abliva's operations. It will also be possible to ask questions to the company. The meeting will mostly be held in Swedish.
Abliva AB is the new name that replaces the former NeuroVive Pharmaceutical AB. The name change is in line with the company's strengthened focus on mitochondrial disease. Abliva's main projects, KL1333 and NV354, are both focused on primary mitochondrial diseases. The company's drug candidate, NeuroSTAT, is planned after non-dilutive financing to be transferred into a separate company to give the project the best opportunities for resource allocation and further development to the market.
Further information on programs and participators will be published shortly. In the meantime, please book the afternoon in your calendars.
A link to the Capital Markets Day will be available on Abliva's website: www.abliva.com.
Questions can be sent to: email@example.com.
Welcome on 23 June!